Larimar Therapeutics
Matthew Baile has extensive work experience in the field of research. Matthew began their career as an Undergraduate Researcher at USAMRIID, the US Army Medical Research Institute of Infectious Diseases, in 2007. Matthew then went on to pursue their graduate studies at The Johns Hopkins University School of Medicine, where they worked as a Graduate Student from 2008 to 2014. Following this, Matthew joined Cornell University as a Postdoctoral Researcher from 2014 to 2020. Since 2020, they have been working at Larimar Therapeutics Inc., starting as a Research Investigator and later being promoted to the position of Senior Research Investigator in July 2021.
Matthew Baile received their Bachelor of Science degree in Biology from Shippensburg University of Pennsylvania from 2004 to 2008. Matthew then pursued further education and obtained a PhD in Biochemistry, Cell, and Molecular Biology from The Johns Hopkins University School of Medicine from 2008 to 2014.
Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.